Flagship Wealth Advisors LLC Invests $34,000 in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Flagship Wealth Advisors LLC bought a new position in GE HealthCare Technologies Inc. (NASDAQ:GEHC) during the fourth quarter, HoldingsChannel.com reports. The fund bought 436 shares of the company’s stock, valued at approximately $34,000.

A number of other institutional investors have also recently modified their holdings of GEHC. D1 Capital Partners L.P. purchased a new stake in shares of GE HealthCare Technologies in the third quarter worth $268,159,000. Van ECK Associates Corp grew its stake in shares of GE HealthCare Technologies by 107.3% in the fourth quarter. Van ECK Associates Corp now owns 4,841,652 shares of the company’s stock worth $378,520,000 after acquiring an additional 2,506,417 shares during the last quarter. State Street Corp grew its stake in shares of GE HealthCare Technologies by 7.8% in the third quarter. State Street Corp now owns 18,615,890 shares of the company’s stock worth $1,747,101,000 after acquiring an additional 1,347,114 shares during the last quarter. Massachusetts Financial Services Co. MA purchased a new stake in shares of GE HealthCare Technologies in the third quarter worth $93,713,000. Finally, Jennison Associates LLC grew its stake in shares of GE HealthCare Technologies by 124.5% in the fourth quarter. Jennison Associates LLC now owns 1,709,635 shares of the company’s stock worth $133,659,000 after acquiring an additional 948,017 shares during the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

GE HealthCare Technologies Stock Down 0.4 %

NASDAQ GEHC opened at $82.14 on Wednesday. The stock’s 50-day moving average price is $87.25 and its 200-day moving average price is $86.10. The company has a quick ratio of 0.83, a current ratio of 1.04 and a debt-to-equity ratio of 0.88. GE HealthCare Technologies Inc. has a 52 week low of $74.51 and a 52 week high of $94.80. The company has a market capitalization of $37.56 billion, a P/E ratio of 18.97, a price-to-earnings-growth ratio of 3.19 and a beta of 1.13.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.26 by $0.19. GE HealthCare Technologies had a return on equity of 25.74% and a net margin of 10.13%. The firm had revenue of $5.32 billion for the quarter, compared to the consensus estimate of $5.33 billion. On average, equities research analysts predict that GE HealthCare Technologies Inc. will post 4.68 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Wells Fargo & Company increased their price objective on GE HealthCare Technologies from $96.00 to $103.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. Jefferies Financial Group raised GE HealthCare Technologies from a “hold” rating to a “buy” rating and increased their price objective for the company from $95.00 to $103.00 in a research report on Wednesday, January 8th. Citigroup increased their price objective on GE HealthCare Technologies from $103.00 to $110.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. Finally, The Goldman Sachs Group raised GE HealthCare Technologies from a “neutral” rating to a “buy” rating and increased their price objective for the company from $85.00 to $100.00 in a research report on Tuesday, March 11th. One analyst has rated the stock with a sell rating, two have given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $98.75.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.